Updated on 2024/10/08

写真a

 
IWAMI Shingo
 
Organization
Graduate School of Science Professor
Graduate School
Graduate School of Science
Undergraduate School
School of Science Department of Biological Science
Title
Professor

Degree 1

  1. 博士（理学） （ 2009.3   静岡大学 ） 

To the head of Degree.▲

Research Interests 3

  1. コンピュータシミュレーション

  2. 数理モデル

  3. 異分野融合生物学

To the head of Research Interests.▲

Research Areas 2

  1. Others / Others  / 応用数学・統計数学

  2. Others / Others  / 超分子機能学

To the head of Research Areas.▲

Research History 4

  1. Nagoya University   Graduate School of Science Division of Biological Science Supramolecular Biology   Professor

    2021.4

  2. Kyushu University

    2021.4

  3. 公益財団法人がん研究会   客員研究員

    2020.4

  4. Kyoto University

    2020.4

To the head of Research History.▲
 

Papers 54

  1. Modelling the effectiveness of an isolation strategy for managing mpox outbreaks with variable infectiousness profiles Reviewed International coauthorship

    Jeong, YD; Hart, WS; Thompson, RN; Ishikane, M; Nishiyama, T; Park, H; Iwamoto, N; Sakurai, A; Suzuki, M; Aihara, K; Watashi, K; op de Coul, E; Ohmagari, N; Wallinga, J; Iwami, S; Miura, F

    NATURE COMMUNICATIONS   Vol. 15 ( 1 ) page： 7112   2024.8

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Nature Communications  

    The global outbreak of mpox in 2022 and subsequent sporadic outbreaks in 2023 highlighted the importance of nonpharmaceutical interventions such as case isolation. Individual variations in viral shedding dynamics may lead to either premature ending of isolation for infectious individuals, or unnecessarily prolonged isolation for those who are no longer infectious. Here, we developed a modeling framework to characterize heterogeneous mpox infectiousness profiles – specifically, when infected individuals cease to be infectious – based on viral load data. We examined the potential effectiveness of three different isolation rules: a symptom-based rule (the current guideline in many countries) and rules permitting individuals to stop isolating after either a fixed duration or following tests that indicate that they are no longer likely to be infectious. Our analysis suggests that the duration of viral shedding ranges from 23 to 50 days between individuals. The risk of infected individuals ending isolation too early was estimated to be 8.8% (95% CI: 6.7–10.5) after symptom clearance and 5.4% (95% CI: 4.1–6.7) after 3 weeks of isolation. While these results suggest that the current standard practice for ending isolation is effective, we found that unnecessary isolation following the infectious period could be reduced by adopting a testing-based rule.

    DOI： 10.1038/s41467-024-51143-w

    Web of Science

    Scopus

    PubMed

  2. Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population Reviewed International coauthorship

    Nakamura N., Kobashi Y., Kim K.S., Park H., Tani Y., Shimazu Y., Zhao T., Nishikawa Y., Omata F., Kawashima M., Yoshida M., Abe T., Saito Y., Senoo Y., Nonaka S., Takita M., Yamamoto C., Kawamura T., Sugiyama A., Nakayama A., Kaneko Y., Jeong Y.D., Tatematsu D., Akao M., Sato Y., Iwanami S., Fujita Y., Wakui M., Aihara K., Kodama T., Shibuya K., Iwami S., Tsubokura M.

    PLOS Digital Health   Vol. 3 ( 5 ) page： e0000497   2024.5

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pdig.0000497

    Scopus

  3. Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers Reviewed International coauthorship

    PLOS COMPUTATIONAL BIOLOGY   Vol. 20 ( 3 ) page： e1011238   2024.3

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pcbi.1011238

    Web of Science

    Scopus

    PubMed

  4. Two-step evolution of HIV-1 budding system leading to pandemic in the human population Reviewed International coauthorship

    Konno, Y; Uriu, K; Chikata, T; Takada, T; Kurita, JI; Ueda, MT; Islam, S; Tan, BJY; Ito, J; Aso, H; Kumata, R; Williamson, C; Iwami, S; Takiguchi, M; Nishimura, Y; Morita, E; Satou, Y; Nakagawa, S; Koyanagi, Y; Sato, K

    Cell Reports   Vol. 43 ( 2 ) page： 113697   2024.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.celrep.2024.113697

    Web of Science

    PubMed

  5. Age-related changes in the hematopoietic stem cell pool revealed via quantifying the balance of symmetric and asymmetric divisions Reviewed International coauthorship

    T Kawahigashi†, S Iwanami†, M Takahashi, J Bhadury, S Iwami and S Yamazaki.

    PLOS ONE   Vol. 19 ( 1 ) page： e0292575   2024.1

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pone.0292575

  6. Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials Reviewed International coauthorship

    Kawaguchi, T; Kawaguchi, A; Hashida, R; Nakano, D; Tsutsumi, T; Kawaguchi, M; Koya, S; Hirota, K; Tomita, M; Tsuchihashi, J; Narao, H; Matsuse, H; Hiraoka, K; Ejima, K; Iwami, S; Yoshio, S

    JOURNAL OF GASTROENTEROLOGY   Vol. 59 ( 3 ) page： 216 - 228   2023.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00535-023-02060-0

    Web of Science

    Scopus

    PubMed

  7. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection Reviewed

    Miyamoto, S; Nishiyama, T; Ueno, A; Park, H; Kanno, T; Nakamura, N; Ozono, S; Aihara, K; Takahashi, K; Tsuchihashi, Y; Ishikane, M; Arashiro, T; Saito, S; Ainai, A; Hirata, Y; Iida, S; Katano, H; Tobiume, M; Tokunaga, K; Fujimoto, T; Suzuki, M; Nagashima, M; Nakagaw, H; Narita, M; Kato, Y; Igari, H; Fujita, K; Kato, T; Hiyama, K; Shindou, K; Adachi, T; Fukushima, K; Nakamura-Uchiyama, F; Hase, R; Yoshimura, Y; Yamato, M; Nozaki, Y; Ohmagari, N; Suzuki, M; Saito, T; Iwami, S; Suzuki, T

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   Vol. 120 ( 52 ) page： e2314808120   2023.12

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1073/pnas.2314808120

    Web of Science

    Scopus

    PubMed

  8. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history Reviewed

    Nishiyama, T; Miyamatsu, Y; Park, H; Nakamura, N; Shibata, RY; Iwami, S; Nagasaki, Y

    VACCINE   Vol. 41 ( 52 ) page： 7655 - 7662   2023.12

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.vaccine.2023.11.040

    Web of Science

    Scopus

    PubMed

  9. Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution Reviewed International coauthorship

    Sunagawa, J; Park, H; Kim, KS; Komorizono, R; Choi, S; Torres, LR; Woo, J; Jeong, YD; Hart, WS; Thompson, RN; Aihara, K; Iwami, S; Yamaguchi, R

    NATURE COMMUNICATIONS   Vol. 14 ( 1 ) page： 7395   2023.11

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41467-023-43043-2

    Web of Science

    Scopus

    PubMed

  10. Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays Reviewed

    Saito, H; Yoshimura, H; Yoshida, M; Tani, Y; Kawashima, M; Uchiyama, T; Zhao, TC; Yamamoto, C; Kobashi, Y; Sawano, T; Imoto, S; Park, H; Nakamura, N; Iwami, S; Kaneko, Y; Nakayama, A; Kodama, T; Wakui, M; Kawamura, T; Tsubokura, M

    VACCINES   Vol. 11 ( 11 ) page： 1694   2023.11

    　More details

  11. Contact-number-driven virus evolution: A multi-level modeling framework for the evolution of acute or persistent RNA virus infection Reviewed International coauthorship

    Sunagawa, J; Komorizono, R; Park, H; Hart, WS; Thompson, RN; Makino, A; Tomonaga, K; Iwami, S; Yamaguchi, R

    PLOS COMPUTATIONAL BIOLOGY   Vol. 19 ( 5 ) page： e1011173   2023.5

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pcbi.1011173

    Web of Science

    Scopus

    PubMed

  12. Stratification of viral shedding patterns in saliva of COVID-19 patients Reviewed International coauthorship

    H. Park, R. Yoshimura, S. Iwanami, K. S. Kim, K. Ejima, N. Nakamura, K. Aihara, Y. Miyazaki, T. Umeyama, K. Miyazawa, T. Morita, K. Watashi, C. B. Brooke, R. Ke, S. Iwami‡ and T. Miyazaki‡ (‡ Equal contribution)

    eLife   Vol. 13   page： RP96032   2024.4

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

  13. Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma Reviewed

    Yamada, A; Yasunaga, J; Liang, LH; Zhang, WY; Sunagawa, J; Nakaoka, S; Iwami, S; Kogure, Y; Ito, Y; Kataoka, K; Nakagawa, M; Iwanaga, M; Utsunomiya, A; Koh, KR; Watanabe, T; Nosaka, K; Matsuoka, M

    CANCER SCIENCE   Vol. 115 ( 1 ) page： 310 - 320   2024.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.15997

    Web of Science

    Scopus

    PubMed

  14. Analysis of the risk and pre-emptive control of viral outbreaks accounting for within-host dynamics: SARS-CoV-2 as a case study Reviewed International coauthorship

    W. S. Hart, H. Park, Y. D. Jeong, K. S. Kim, R. Yoshimura, R. N. Thompson† and S. Iwami

    Proceedings of the National Academy of Sciences of the United States of America   Vol. 120 ( 41 ) page： e2305451120   2023.10

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1073/pnas.2305451120

  15. A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 Reviewed

    T. Miyazaki, N. Hosogaya, Y. Fukushige, S. Takemori, S. Morimoto, H. Yamamoto, M. Hori, Y. Ozawa, Y. Shiko, Y. Inaba, T. Kurokawa, H. Hanaoka, S. Iwanami, K. Kim, S. Iwami, K. Watashi, K. Miyazawa, T. Umeyama, S. Yamagoe, Y. Miyazaki, T. Wakita, M. Sumiyoshi, T. Hirayama, K. Izumikawa, K. Yanagihara, H. Mukae, H. Kawasuji, Y. Yamamoto, N. Tarumoto, H. Ishii, H. Ohno, K. Yatera, H. Kakeya, Y. Kichikawa, Y. Kato, T. Matsumoto, M. Saito, H. Yotsuyanagi and S. Kohno.

    Microbiology Spectrum   Vol. 11 ( 3 ) page： e0431122   2023.6

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1128/spectrum.04311-22

  16. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir Reviewed

    S.Torii†, K.S.Kim†, J.Koseki†, R.Suzuki†, S.Iwanami, Y.Fujita, Y.D.Jeong, J.Ito, H.Asakura, M.Nagashima, K.Sadamasu, K.Yoshimura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K.Sato, Y. Matsuura, T.Shimamura, S.Iwami, T.Fukuhara

    PLOS Pathogens   Vol. 19 ( 3 ) page： e1011231   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.ppat.1011231

  17. Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors Reviewed International coauthorship

    Tatematsu Daiki, Akao Marwa, Park Hyeongki, Iwami Shingo, Ejima Keisuke, Iwanami Shoya

    JOURNAL OF THEORETICAL BIOLOGY   Vol. 561   page： 111403   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jtbi.2022.111403

    Web of Science

    Scopus

    PubMed

  18. Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments Reviewed International coauthorship

    D. Akazawa¶, H. Ohashi¶, T. Hishiki&, T. Morita&, S. Iwanami†, K. S. Kim†, Y. D. Jeong†, E. S. Park, M. Kataoka, K. Shionoya, J. Mifune, K. Tsuchimoto, S. Ojima, A. H. Azam, S. Nakajima, H. Park, T. Yoshikawa, M. Shimojima, K. Kiga, S. Iwami, K. Maeda, T. Suzuki, H. Ebihara, Y. Takahashi and K. Watashi

    Journal of Infectious Diseases   Vol. 228 ( 5 ) page： 591 - 603   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/infdis/jiad058

  19. The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants Reviewed International coauthorship

    Thompson Robin N., Southall Emma, Daon Yair, Lovell-Read Francesca A., Iwami Shingo, Thompson Craig P., Obolski Uri

    FRONTIERS IN IMMUNOLOGY   Vol. 13   page： 1049458   2023.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3389/fimmu.2022.1049458

    Web of Science

    Scopus

    PubMed

  20. Smoking enhances the expression of angiotensin-converting enzyme 2 involved in the efficiency of severe acute respiratory syndrome coronavirus 2 infection Reviewed

    Suzuki Rigel, Ono Yuki, Noshita Koji, Kim Kwang Su, Ito Hayato, Morioka Yuhei, Tamura Tomokazu, Okuzaki Daisuke, Tagawa Tetsuzo, Takenaka Tomoyoshi, Yoshizumi Tomoharu, Shimamura Teppei, Iwami Shingo, Fukuhara Takasuke

    MICROBIOLOGY AND IMMUNOLOGY   Vol. 67 ( 1 ) page： 22 - 31   2023.1

    　More details

  21. Detecting time-evolving phenotypic components of adverse reactions against BNT162b2 SARS-CoV-2 vaccine via non-negative tensor factorization Reviewed

    Ikeda Kei, Nakada Taka-Aki, Kageyama Takahiro, Tanaka Shigeru, Yoshida Naoki, Ishikawa Tetsuo, Goshima Yuki, Otaki Natsuko, Iwami Shingo, Shimamura Teppei, Taniguchi Toshibumi, Igari Hidetoshi, Hanaoka Hideki, Yokote Koutaro, Tsuyuzaki Koki, Nakajima Hiroshi, Kawakami Eiryo

    iScience   Vol. 25 ( 10 ) page： 105237   2022.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.isci.2022.105237

    Web of Science

    Scopus

    PubMed

  22. A direct comparison of methods for assessing the threat from emerging infectious diseases in seasonally varying environments Reviewed International coauthorship

    Kaye A. R., Hart W. S., Bromiley J., Iwami S., Thompson R. N.

    JOURNAL OF THEORETICAL BIOLOGY   Vol. 548   page： 111195   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Journal of Theoretical Biology  

    Seasonal variations in environmental conditions lead to changing infectious disease epidemic risks at different times of year. The probability that early cases initiate a major epidemic depends on the season in which the pathogen enters the population. The instantaneous epidemic risk (IER) can be tracked. This quantity is straightforward to calculate, and corresponds to the probability of a major epidemic starting from a single case introduced at time t=t0, assuming that environmental conditions remain identical from that time onwards (i.e. for all t≥t0). However, the threat when a pathogen enters the population in fact depends on changes in environmental conditions occurring within the timescale of the initial phase of the outbreak. For that reason, we compare the IER with a different metric: the case epidemic risk (CER). The CER corresponds to the probability of a major epidemic starting from a single case entering the population at time t=t0, accounting for changes in environmental conditions after that time. We show how the IER and CER can be calculated using different epidemiological models (the stochastic Susceptible-Infectious-Removed model and a stochastic host-vector model that is parameterised using temperature data for Miami) in which transmission parameter values vary temporally. While the IER is always easy to calculate numerically, the adaptable method we provide for calculating the CER for the host-vector model can also be applied easily and solved using widely available software tools. In line with previous research, we demonstrate that, if a pathogen is likely to either invade the population or fade out on a fast timescale compared to changes in environmental conditions, the IER closely matches the CER. However, if this is not the case, the IER and the CER can be significantly different, and so the CER should be used. This demonstrates the need to consider future changes in environmental conditions carefully when assessing the risk posed by emerging pathogens.

    DOI： 10.1016/j.jtbi.2022.111195

    Web of Science

    Scopus

  23. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 Reviewed International coauthorship

    Ohashi Hirofumi, Hishiki Takayuki, Akazawa Daisuke, Kim Kwang Su, Woo Joohyeon, Shionoya Kaho, Tsuchimoto Kana, Iwanami Shoya, Moriyama Saya, Kinoshita Hitomi, Yamada Souichi, Kuroda Yudai, Yamamoto Tsukasa, Kishida Noriko, Watanabe Shinji, Hasegawa Hideki, Suzuki Tadaki, Maeda Ken, Fukushi Shuetsu, Takahashi Yoshimasa, Iwami Shingo, Watashi Koichi

    ANTIVIRAL RESEARCH   Vol. 205   page： 105372   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Antiviral Research  

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment.

    DOI： 10.1016/j.antiviral.2022.105372

    Web of Science

    Scopus

    PubMed

  24. Designing isolation guidelines for COVID-19 patients with rapid antigen tests Reviewed International coauthorship International journal

    Jeong Yong Dam, Ejima Keisuke, Kim Kwang Su, Joohyeon Woo, Iwanami Shoya, Fujita Yasuhisa, Jung Il Hyo, Aihara Kazuyuki, Shibuya Kenji, Iwami Shingo, Bento Ana I, Ajelli Marco

    NATURE COMMUNICATIONS   Vol. 13 ( 1 ) page： 4910   2022.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Nature Communications  

    Appropriate isolation guidelines for COVID-19 patients are warranted. Currently, isolating for fixed time is adopted in most countries. However, given the variability in viral dynamics between patients, some patients may no longer be infectious by the end of isolation, whereas others may still be infectious. Utilizing viral test results to determine isolation length would minimize both the risk of prematurely ending isolation of infectious patients and the unnecessary individual burden of redundant isolation of noninfectious patients. In this study, we develop a data-driven computational framework to compute the population-level risk and the burden of different isolation guidelines with rapid antigen tests (i.e., lateral flow tests). Here, we show that when the detection limit is higher than the infectiousness threshold values, additional consecutive negative results are needed to ascertain infectiousness status. Further, rapid antigen tests should be designed to have lower detection limits than infectiousness threshold values to minimize the length of prolonged isolation.

    DOI： 10.1038/s41467-022-32663-9

    Web of Science

    Scopus

    PubMed

  25. Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study Reviewed International coauthorship

    Ejima Keisuke, Kim Kwang Su, Bento Ana I, Iwanami Shoya, Fujita Yasuhisa, Aihara Kazuyuki, Shibuya Kenji, Iwami Shingo

    BMC INFECTIOUS DISEASES   Vol. 22 ( 1 ) page： 656   2022.7

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：BMC Infectious Diseases  

    Background: Multiple waves of the COVID-19 epidemic have hit most countries by the end of 2021. Most of those waves are caused by emergence and importation of new variants. To prevent importation of new variants, combination of border control and contact tracing is essential. However, the timing of infection inferred by interview is influenced by recall bias and hinders the contact tracing process. Methods: We propose a novel approach to infer the timing of infection, by employing a within-host model to capture viral load dynamics after the onset of symptoms. We applied this approach to ascertain secondary transmission which can trigger outbreaks. As a demonstration, the 12 initial reported cases in Singapore, which were considered as imported because of their recent travel history to Wuhan, were analyzed to assess whether they are truly imported. Results: Our approach suggested that 6 cases were infected prior to the arrival in Singapore, whereas other 6 cases might have been secondary local infection. Three among the 6 potential secondary transmission cases revealed that they had contact history to previously confirmed cases. Conclusions: Contact trace combined with our approach using viral load data could be the key to mitigate the risk of importation of new variants by identifying cases as early as possible and inferring the timing of infection with high accuracy.

    DOI： 10.1186/s12879-022-07646-2

    Web of Science

    Scopus

    PubMed

  26. Maternal embryonic leucine zipper kinase (MELK) optimally regulates the HIV-1 uncoating process Reviewed

    Nishiyama Takara, Takada Toru, Takeuchi Hiroaki, Iwami Shingo

    JOURNAL OF THEORETICAL BIOLOGY   Vol. 545   page： 111152   2022.7

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Journal of Theoretical Biology  

    Human immunodeficiency virus type-1 (HIV-1) attaches to target cells and releases the capsid, an essential component of the viral core that contains viral RNA, into the cytoplasm. After invading target cells, the core structure gradually collapses. The timing of the disassembly of the HIV-1 capsid is essential for efficient viral cDNA synthesis and transport into the nucleus. HIV-1 uncoating is controlled by the host factor maternal embryonic leucine zipper kinase (MELK); however, the quantitative and dynamic relationship between the HIV-1 uncoating process and HIV-1 infection remains unresolved. In this study, we quantified the uncoating process on HIV-1 cDNA synthesis and transport into the nucleus by combining a mathematical model with in vitro data. In addition, detailed in silico simulations demonstrated host factors, including MELK, optimize transport efficiency. Our experimental-mathematical approach revealed quantitative dynamics of the HIV-1 uncoating process, indicating that increasing the speed of uncoating always reduces the amount of HIV-1 cDNA in the nucleus.

    DOI： 10.1016/j.jtbi.2022.111152

    Web of Science

    Scopus

    PubMed

  27. Antithetic effect of interferon-alpha on cell-free and cell-to-cell HIV-1 infection Reviewed International coauthorship International journal

    Kumata Ryuichi, Iwanami Shoya, Mar Katrina B., Kakizoe Yusuke, Misawa Naoko, Nakaoka Shinji, Koyanagi Yoshio, Perelson Alan S., Schoggins John W., Iwami Shingo, Sato Kei

    PLOS COMPUTATIONAL BIOLOGY   Vol. 18 ( 4 ) page： e1010053   2022.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：PLoS Computational Biology  

    In HIV-1-infected individuals, transmitted/founder (TF) virus contributes to establish new infection and expands during the acute phase of infection, while chronic control (CC) virus emerges during the chronic phase of infection. TF viruses are more resistant to interferon-alpha (IFN-α)-mediated antiviral effects than CC virus, however, its virological relevance in infected individuals remains unclear. Here we perform an experimental-mathematical investigation and reveal that IFN-α strongly inhibits cell-to-cell infection by CC virus but only weakly affects that by TF virus. Surprisingly, IFN-α enhances cell-free infection of HIV-1, particularly that of CC virus, in a virus-cell density-dependent manner. We further demonstrate that LY6E, an IFN-stimulated gene, can contribute to the density-dependent enhancement of cell-free HIV-1 infection. Altogether, our findings suggest that the major difference between TF and CC viruses can be explained by their resistance to IFN-α-mediated inhibition of cell-to-cell infection and their sensitivity to IFN-α-mediated enhancement of cell-free infection.

    DOI： 10.1371/journal.pcbi.1010053

    Web of Science

    Scopus

    PubMed

  28. Optimal Feedback Control of Cancer Chemotherapy Using Hamilton-Jacobi-Bellman Equation International coauthorship International journal

    Jeong Yong Dam, Kim Kwang Su, Roh Yunil, Choi Sooyoun, Iwami Shingo, Jung Il Hyo

    COMPLEXITY   Vol. 2022   page： 2158052   2022.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Complexity  

    Cancer chemotherapy has been the most common cancer treatment. However, it has side effects that kill both tumor cells and immune cells, which can ravage the patient's immune system. Chemotherapy should be administered depending on the patient's immunity as well as the level of cancer cells. Thus, we need to design an efficient treatment protocol. In this work, we study a feedback control problem of tumor-immune system to design an optimal chemotherapy strategy. For this, we first propose a mathematical model of tumor-immune interactions and conduct stability analysis of two equilibria. Next, the feedback control is found by solving the Hamilton-Jacobi-Bellman (HJB) equation. Here, we use an upwind finite-difference method for a numerical approximate solution of the HJB equation. Numerical simulations show that the feedback control can help determine the treatment protocol of chemotherapy for tumor and immune cells depending on the side effects.

    DOI： 10.1155/2022/2158052

    Web of Science

    Scopus

  29. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey Reviewed International journal

    Yoshida Makoto, Kobashi Yurie, Kawamura Takeshi, Shimazu Yuzo, Nishikawa Yoshitaka, Omata Fumiya, Zhao Tianchen, Yamamoto Chika, Kaneko Yudai, Nakayama Aya, Takita Morihito, Ito Naomi, Kawashima Moe, Sugiura Sota, Shibuya Kenji, Iwami Shingo, Kim Kwangsu, Iwanami Shoya, Kodama Tatsuhiko, Tsubokura Masaharu

    Vaccines   Vol. 10 ( 4 ) page： 515   2022.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Vaccines  

    This was a retrospective cohort study, which aimed to investigate the factors associated with hesitancy to receive a third dose of a coronavirus disease 2019 (COVID-19) vaccine. A paper-based questionnaire survey was administered to all participants. This study included participants who provided answers in the questionnaire about whether they had an intent to receive a third dose of a vaccine. Data on sex, age, area of residence, adverse reactions after the second vaccination, whether the third vaccination was desired, and reasons to accept or hesitate over the booster vaccination were retrieved. Among the 2439 participants, with a mean (±SD) age of 52.6 ± 18.9 years, and a median IgG-S antibody titer of 324.9 (AU/mL), 97.9% of participants indicated their intent to accept a third vaccination dose. The logistic regression revealed that participants of a younger age (OR = 0.98; 95% CI: 0.96–1.00) and with a higher antibody level (OR = 2.52; 95% CI: 1.27–4.99) were positively associated with hesitancy over the third vaccine. The efficacy of the COVID-19 vaccine and concerns about adverse reactions had a significant impact on behavior regarding the third vaccination. A rapid increase in the booster dose rate is needed to control the pandemic, and specific approaches should be taken with these groups that are likely to hesitate over the third vaccine, subsequently increasing booster contact rate.

    DOI： 10.3390/vaccines10040515

    Web of Science

    Scopus

    PubMed

  30. Escaping stochastic extinction of mutant virus: Temporal pattern of emergence of drug resistance within a host Reviewed

    Hayashi R., Iwami S., Iwasa Y.

    Journal of Theoretical Biology   Vol. 537   page： 111029   2022.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jtbi.2022.111029

    Scopus

    PubMed

  31. Evaluating the cost-effectiveness of a pre-exposure prophylaxis program for HIV prevention for men who have sex with men in Japan Reviewed

    Yamamoto N., Koizumi Y., Tsuzuki S., Ejima K., Takano M., Iwami S., Mizushima D., Oka S.

    Scientific Reports   Vol. 12 ( 1 ) page： 3088   2022.2

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-022-07116-4

    Scopus

    PubMed

  32. Designing isolation guidelines for COVID-19 patients utilizing rapid antigen tests: a simulation study using viral dynamics models.

    Jeong YD, Ejima K, Kim KS, Joohyeon W, Iwanami S, Fujita Y, Jung IH, Shibuya K, Iwami S, Bento AI, Ajelli M

    Translational and Regulatory Sciences     2022.1

    　More details

    Language：English  

    DOI： 10.1101/2022.01.24.22269769

    PubMed

  33. A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro Reviewed International coauthorship

    K. Matsuda, S. Islam, T. Takada, K. Tsuchiya, B.J. Yang Tan, S. Hattori, H. Katsuya, K. Kitagawa, K.S. Kim, M. Matsuo, K. Sugata, N.S. Delino, H. Gatanaga, K. Yoshimura, S. Matsushita, H. Mitsuya, S. Iwami, Y. Satou, and K. Maeda.

    Cell Reports Methods   Vol. 1 ( 8 ) page： 100122   2021.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： https://doi.org/10.1016/j.crmeth.2021.100122

  34. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection Reviewed

    Kim K.S., Iwanami S., Oda T., Fujita Y., Kuba K., Miyazaki T., Ejima K., Iwami S.

    Life Science Alliance   Vol. 4 ( 10 )   2021.8

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.26508/LSA.202101049

    Scopus

    PubMed

  35. Revisiting the guidelines for ending isolation for COVID-19 patients Reviewed

    Jeong Yong Dam, Ejima Keisuke, Kim Kwang Su, Iwanami Shoya, Bento Ana I, Fujita Yasuhisa, Jung Il Hyo, Aihara Kazuyuki, Watashi Koichi, Miyazaki Taiga, Wakita Takaji, Iwami Shingo, Ajelli Marco

    eLife   Vol. 10   2021.7

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Since the start of the COVID-19 pandemic, two mainstream guidelines for defining when to end the isolation of SARS-CoV-2-infected individuals have been in use: the one-size-fits-all approach (i.e. patients are isolated for a fixed number of days) and the personalized approach (i.e. based on repeated testing of isolated patients). We use a mathematical framework to model within-host viral dynamics and test different criteria for ending isolation. By considering a fixed time of 10 days since symptom onset as the criterion for ending isolation, we estimated that the risk of releasing an individual who is still infectious is low (0–6.6%). However, this policy entails lengthy unnecessary isolations (4.8–8.3 days). In contrast, by using a personalized strategy, similar low risks can be reached with shorter prolonged isolations. The obtained findings provide a scientific rationale for policies on ending the isolation of SARS-CoV-2-infected individuals.

    DOI： 10.7554/eLife.69340

    Web of Science

    Scopus

    PubMed

  36. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study combined with clinical data Reviewed

    Iwanami Shoya, Ejima Keisuke, Kim Kwang Su, Noshita Koji, Fujita Yasuhisa, Miyazaki Taiga, Kohno Shigeru, Miyazaki Yoshitsugu, Morimoto Shimpei, Nakaoka Shinji, Koizumi Yoshiki, Asai Yusuke, Aihara Kazuyuki, Watashi Koichi, Thompson Robin N., Shibuya Kenji, Fujiu Katsuhito, Perelson Alan S., Iwami Shingo, Wakita Takaji

    PLOS Medicine   Vol. 18 ( 7 ) page： e1003660   2021.7

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Background Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence from clinical studies is limited. The lack of evidence from clinical trials may stem in part from the imperfect design of the trials. We investigated how clinical trials for antivirals need to be designed, especially focusing on the sample size in randomized controlled trials Methods and findings A modeling study was conducted to help understand the reasons behind inconsistent clinical trial findings and to design better clinical trials. We first analyzed longitudinal viral load data for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) without antiviral treatment by use of a within-host virus dynamics model. The fitted viral load was categorized into 3 different groups by a clustering approach. Comparison of the estimated parameters showed that the 3 distinct groups were characterized by different virus decay rates (p-value < 0.001). The mean decay rates were 1.17 d-1 (95% CI: 1.06 to 1.27 d-1), 0.777 d-1 (0.716 to 0.838 d-1), and 0.450 d-1 (0.378 to 0.522 d-1) for the 3 groups, respectively. Such heterogeneity in virus dynamics could be a confounding variable if it is associated with treatment allocation in compassionate use programs (i.e., observational studies). Subsequently, we mimicked randomized controlled trials of antivirals by simulation. An antiviral effect causing a 95% to 99% reduction in viral replication was added to the model. To be realistic, we assumed that randomization and treatment are initiated with some time lag after symptom onset. Using the duration of virus shedding as an outcome, the sample size to detect a statistically significant mean difference between the treatment and placebo groups (1:1 allocation) was 13,603 and 11,670 (when the antiviral effect was 95% and 99%, respectively) per group if all patients are enrolled regardless of timing of randomization. The sample size was reduced to 584 and 458 (when the antiviral effect was 95% and 99%, respectively) if only patients who are treated within 1 day of symptom onset are enrolled. We confirmed the sample size was similarly reduced when using cumulative viral load in log scale as an outcome. We used a conventional virus dynamics model, which may not fully reflect the detailed mechanisms of viral dynamics of SARS-CoV-2. The model needs to be calibrated in terms of both parameter settings and model structure, which would yield more reliable sample size calculation. Conclusions In this study, we found that estimated association in observational studies can be biased due to large heterogeneity in viral dynamics among infected individuals, and statistically significant effect in randomized controlled trials may be difficult to be detected due to small sample size. The sample size can be dramatically reduced by recruiting patients immediately after developing symptoms. We believe this is the first study investigated the study design of clinical trials for antiviral treatment using the viral dynamics model.

    DOI： 10.1371/journal.pmed.1003660

    Web of Science

    Scopus

    PubMed

  37. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro Reviewed

    Shionoya Kaho, Yamasaki Masako, Iwanami Shoya, Ito Yusuke, Fukushi Shuetsu, Ohashi Hirofumi, Saso Wakana, Tanaka Tomohiro, Aoki Shin, Kuramochi Kouji, Iwami Shingo, Takahashi Yoshimasa, Suzuki Tadaki, Muramatsu Masamichi, Takeda Makoto, Wakita Takaji, Watashi Koichi

    FRONTIERS IN MICROBIOLOGY   Vol. 12   page： 651403   2021.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher antiviral potency, we screened approved anti-parasitic/anti-protozoal drugs and identified an anti-malarial drug, Mefloquine, which showed the highest anti-SARS-CoV-2 activity among the tested compounds. Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 1.28 μM, IC90 = 2.31 μM, and IC99 = 4.39 μM in VeroE6/TMPRSS2 cells. Mefloquine inhibited viral entry after viral attachment to the target cell. Combined treatment with Mefloquine and Nelfinavir, a replication inhibitor, showed synergistic antiviral activity. Our mathematical modeling based on the drug concentration in the lung predicted that Mefloquine administration at a standard treatment dosage could decline viral dynamics in patients, reduce cumulative viral load to 7% and shorten the time until virus elimination by 6.1 days. These data cumulatively underscore Mefloquine as an anti-SARS-CoV-2 entry inhibitor.

    DOI： 10.3389/fmicb.2021.651403

    Web of Science

    Scopus

    PubMed

  38. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial. Reviewed

    Hosogaya N, Miyazaki T, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Kurokawa T, Kawasaki Y, Hanawa M, Fujii Y, Hanaoka H, Iwami S, Watashi K, Yamagoe S, Miyazaki Y, Wakita T, Izumikawa K, Yanagihara K, Mukae H, Kohno S, Nelfinavir Study Group.

    Trials   Vol. 22 ( 1 ) page： 309   2021.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s13063-021-05282-w

    PubMed

  39. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment Reviewed International coauthorship

    Hirofumi Ohashi;Koichi Watashi;Wakana Saso;Kaho Shionoya;Shoya Iwanami;Takatsugu Hirokawa;Tsuyoshi Shirai;Shigehiko Kanaya;Yusuke Ito;Kwang Su Kim;Takao Nomura;Tateki Suzuki;Kazane Nishioka;Shuji Ando;Keisuke Ejima;Yoshiki Koizumi;Tomohiro Tanaka;Shin Aoki;Kouji Kuramochi;Tadaki Suzuki;Takao Hashiguchi;Katsumi Maenaka;Tetsuro Matano;Masamichi Muramatsu;Masayuki Saijo;Kazuyuki Aihara;Shingo Iwami;Makoto Takeda;Jane A. McKeating;Takaji Wakita

    iScience   Vol. 24 ( 4 ) page： 102367 - 102367   2021.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： https://doi.org/10.1016/j.isci.2021.102367

  40. Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. Reviewed

    Ejima K, Kim KS, Iwanami S, Fujita Y, Li M, Zoh RS, Aihara K, Miyazaki T, Wakita T, Iwami S

    Journal of the Royal Society, Interface   Vol. 18 ( 177 ) page： 20200947   2021.4

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1098/rsif.2020.0947

    PubMed

  41. Estimation of the incubation period of COVID-19 using viral load data. Reviewed

    Ejima K, Kim KS, Ludema C, Bento AI, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Watashi K, Aihara K, Nishiura H, Iwami S

    Epidemics   Vol. 35   page： 100454   2021.3

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.epidem.2021.100454

    PubMed

  42. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. Reviewed

    Kim KS, Ejima K, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Asai Y, Nakaoka S, Watashi K, Aihara K, Thompson RN, Ke R, Perelson AS, Iwami S

    PLoS biology   Vol. 19 ( 3 ) page： e3001128   2021.3

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pbio.3001128

    PubMed

  43. HIV testing by public health centers and municipalities and new HIV cases during the COVID-19 pandemic in Japan. Reviewed

    Ejima K, Koizumi Y, Yamamoto N, Rosenberg M, Ludema C, Bento AI, Yoneoka D, Ichikawa S, Mizushima D, Iwami S

    Journal of acquired immune deficiency syndromes (1999)     2021.2

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/QAI.0000000000002660

    PubMed

  44. Quantifying antiviral effects against simian/human immunodeficiency virus induced by host immune response. Reviewed

    Oda T, Kim KS, Fujita Y, Ito Y, Miura T, Iwami S

    Journal of theoretical biology   Vol. 509   page： 110493   2021.1

    　More details

    Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jtbi.2020.110493

    PubMed

  45. Modeling HIV multiple infection. Reviewed

    Guo T, Qiu Z, Kitagawa K, Iwami S, Rong L

    Journal of theoretical biology   Vol. 509   page： 110502   2021.1

    　More details

    Language：English  

    DOI： 10.1016/j.jtbi.2020.110502

    PubMed

  46. Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection Reviewed

    Inagaki Tomoki, Sato Yoshitaka, Ito Jumpei, Takaki Mitsuaki, Okuno Yusuke, Yaguchi Masahiro, Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Kei, Iwami Shingo, Murata Takayuki, Kimura Hiroshi

    FRONTIERS IN MICROBIOLOGY   Vol. 11   page： 575255   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3389/fmicb.2020.575255

    Web of Science

    Scopus

    PubMed

  47. Required concentration index quantifies effective drug combinations against hepatitis C virus infection. Reviewed

    Kakizoe Y, Koizumi Y, Ikoma Y, Ohashi H, Wakita T, Iwami S, Watashi K

    Theoretical Biology and Medical Modelling   Vol. 18 ( 1 ) page： 4   2021.1

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s12976-020-00135-6

    PubMed

  48. Identification of novel avian and mammalian deltaviruses provides new insights into deltavirus evolution. Reviewed

    Iwamoto M, Shibata Y, Kawasaki J, Kojima S, Li YT, Iwami S, Muramatsu M, Wu HL, Wada K, Tomonaga K, Watashi K, Horie M

    Virus evolution   Vol. 7 ( 1 ) page： veab003   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/ve/veab003

    PubMed

  49. Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials Reviewed

    AKAO Marwa, WOO Joohyeon, IWAMI Shingo, IWANAMI Shoya

    Translational and Regulatory Sciences   Vol. 3 ( 3 ) page： 85 - 88   2021

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Catalyst Unit  

    <p>To evaluate the effects of antiviral drugs against coronavirus disease (COVID-19), we calculated the sample size needed to detect significant differences in daily viral load in randomized controlled trials. While calculating sample sizes, simulated viral loads that mimicked longitudinal clinical data were used. The sample size computed from the viral load was the smallest 2 to 4 days after trial participation, while the smallest sample size computed from the positive rate was 4 to 7 days after clinical trial participation.</p>

    DOI： 10.33611/trs.2021-025

    CiNii Research

  50. Modeling Borna Disease Virus in Vitro Spread Reveals the Mode of Antiviral Effect Conferred by an Endogenous Bornavirus-Like Element. Reviewed

    Kim KS, Yamamoto Y, Nakaoka S, Tomonaga K, Iwami S, Honda T

    Journal of virology   Vol. 94 ( 21 )   2020.10

    　More details

    Language：English  

    DOI： 10.1128/JVI.01204-20

    PubMed

  51. Modeling the efficiency of filovirus entry into cells in vitro: Effects of SNP mutations in the receptor molecule. Reviewed

    Kim KS, Kondoh T, Asai Y, Takada A, Iwami S

    PLoS computational biology   Vol. 16 ( 9 ) page： e1007612   2020.9

    　More details

    Language：English  

    DOI： 10.1371/journal.pcbi.1007612

    PubMed

  52. Quantifying the antiviral effect of APOBEC3 on HIV-1 infection in humanized mouse model. Reviewed

    Kurusu T, Kim KS, Koizumi Y, Nakaoka S, Ejima K, Misawa N, Koyanagi Y, Sato K, Iwami S

    Journal of theoretical biology   Vol. 498   page： 110295   2020.8

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jtbi.2020.110295

    PubMed

  53. Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma. Reviewed

    Iwanami S, Kitagawa K, Ohashi H, Asai Y, Shionoya K, Saso W, Nishioka K, Inaba H, Nakaoka S, Wakita T, Diekmann O, Iwami S, Watashi K

    PLoS biology   Vol. 18 ( 7 ) page： e3000562   2020.7

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pbio.3000562

    PubMed

  54. The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network. Reviewed

    Iwamoto M, Saso W, Nishioka K, Ohashi H, Sugiyama R, Ryo A, Ohki M, Yun JH, Park SY, Ohshima T, Suzuki R, Aizaki H, Muramatsu M, Matano T, Iwami S, Sureau C, Wakita T, Watashi K

    The Journal of biological chemistry   Vol. 295 ( 3 ) page： 800 - 807   2020.1

    　More details

    Language：English  

    DOI： 10.1074/jbc.AC119.010366

    PubMed

▼display all

To the head of Papers.▲

Books 4

  1. ウイルス感染の数理モデルとシミュレーション : データを定量的に理解する

    岩見 真吾 , 中岡 慎治, 岩波 翔也（ Role： Joint author）

    共立出版  2024.2  （ ISBN:9784320115538 ）

    　More details

    Language：Japanese

    CiNii Books

  2. 実験医学「感染症のデータサイエンス-いかに感染を制御するのか？どうやって治療をデザインするのか？」 Reviewed

    川上英良，岩見真吾／企画. （ Role： Joint author）

    羊土社  2022.8 

    　More details

    Responsible for pages：2084-2088   Language：Japanese Book type：Scholarly book

  3. ネオウイルス学 Reviewed

    集英社  2021.3 

  4. シリーズ現象を解明する数学　「ウイルス感染と常微分方程式」 Reviewed

    共立出版  2017.4 

To the head of Books.▲

MISC 7

  1. 新型コロナウイルスワクチンのブースター接種による誘導抗体動態の定量的解

    西山尚来，宮松雄一郎，朴炯基，横川理沙，長崎洋司，岩見真吾

    実験医学   Vol. 41   page： 2551 - 2556   2023

    　More details

    Authorship：Last author  

  2. 「ウイルス」にはインドア派とアウトドア派がいる？！ Reviewed

    岩見真吾

    教育科学/数学教育   Vol. 63   page： 28 - 29   2022.2

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  3. 新型コロナウイルス感染症研究のデジタルトランスフォーメーション Reviewed

    ウイルス   Vol. 72   page： 39 - 46   2022

    　More details

    Language：Japanese  

  4. 疾患の数理モデリングと定量的データ解析 Reviewed

    岩波翔也、チョン ヨンダム、キム クァンス、江島啓介、岩見真吾

    数理科学   ( 699 ) page： 16 - 22   2021.9

  5. B型肝炎ウイルスの定量的侵入動態解析 Reviewed

    岩見真吾, キム クァンス

    ファルマシア   Vol. 56 ( 12 ) page： 1104 - 1008   2020.9

    　More details

    Language：Japanese  

  6. 新型コロナウイルスの生体内感染動態の定量化とその応用 Reviewed

    岩波翔也, キム クァンス, 藤田泰久, 江島啓介, 岩見真吾

    数学セミナー   Vol. 59 ( 9 ) page： 33 - 39   2020.9

    　More details

    Language：Japanese  

  7. HTLV-1感染動態の数理モデル型定量的データ解析 Reviewed

    高木舜晟, 安永純一朗, 松岡雅雄, 岩見真吾

    実験医学増刊   Vol. 37 ( 20 )   2019.12

    　More details

    Language：Japanese  

▼display all

To the head of MISC.▲

Presentations 23

  1. 感染症研究のデータサイエンス Invited

    岩見真吾

    第20回霊長類医科学フォーラムプログラム  2024.11.8 

    　More details

    Event date： 2024.11

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  2. Quantifying and stratifying primary and booster COVID-19 vaccine-elicited antibody dynamics in Fukushima Vaccination Cohort in Japan Invited International conference

    Shingo Iwami

    Utilization of Antibody Data-based Mathematical/Statistical Modeling  2024.8.12 

    　More details

    Event date： 2024.8

    Language：English   Presentation type：Oral presentation (invited, special)  

  3. 時系列バイオマーカーの数理モデリングと定量的未来予測 Invited

    岩見真吾

    第45回日本炎症・再生医学会 シンポジウム1 : 健康・未病・疾患の”バイオと数理の融合による”謎解き ～ムーンショット型研究開発事業目標2の展望～  2024.7.17 

    　More details

    Event date： 2024.7

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  4. Stratification of viral shedding patterns in saliva of COVID-19 patients Invited International conference

    Shingo Iwami

    KSMB-SMB 2024: Heterogeneity and adaptation in mathematical biology  2024.7.2 

    　More details

    Event date： 2024.6 - 2024.7

    Language：English   Presentation type：Oral presentation (invited, special)  

  5. Quantifying COVID-19 vaccine-elicited immune responses Invited International conference

    Shingo Iwami

    International Symposium: Data-Driven Mathematical Modeling and Statistical Analysis for Epidemic Control Strategies against Novel Infectious Diseases  2024.6.29 

    　More details

    Event date： 2024.6

    Language：English   Presentation type：Oral presentation (invited, special)  

  6. Modeling clade I mpox lesion transition dynamics - A retrospective analysis of clinical data in DRC - Invited International conference

    Shingo Iwami

    U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim  2024.3.6 

    　More details

    Event date： 2024.3

    Presentation type：Oral presentation (invited, special)  

  7. 異分野融合アプローチを駆使した創薬DX研究 Invited

    岩見真吾

    第97回 日本薬理学会年会  2023.12.15 

    　More details

    Event date： 2023.12

    Presentation type：Oral presentation (invited, special)  

  8. ウイルス学におけるデジタルツインアプローチの役割 Invited

    岩見真吾

    第70回日本ウイルス学会学術集会  2023.9.28 

    　More details

    Event date： 2023.9

    Presentation type：Oral presentation (invited, special)  

  9. 急性肝不全の未来予測

    岩見真吾

    2023年 日本数理生物学会年会  2023.9.4 

    　More details

    Event date： 2023.9

    Presentation type：Oral presentation (general)  

    Venue：奈良女子大学  

  10. Modeling and characterizing vaccine-elicited antibody responses Invited International conference

    Shingo Iwami

    ICIAM 2023 TOKYO Computational Biology: Session I  2023.8.23 

    　More details

    Event date： 2023.8

    Presentation type：Oral presentation (invited, special)  

  11. A case study of Fukushima vaccination cohort - Real world application (II) International conference

    Shingo Iwami

    2023 China-India-Japan-Korea International Conference on Mathematical and Theoretical Biology  2023.6.28 

    　More details

    Event date： 2023.6 - 2023.7

    Presentation type：Oral presentation (general)  

  12. 新興感染症の異分野融合研究：時系列バイオマーカーのデータサイエンス Invited

    岩見真吾

    第97回日本感染症学会総会・学術講演会 第71回日本化学療法学会学術集会 合同学会  2023.4.29 

    　More details

    Event date： 2023.4

    Presentation type：Oral presentation (invited, special)  

  13. 数理モデル駆動型の未病研究 -不均一性と層別化- Invited

    岩見真吾

    日本生理学会第100回記念大会  2023.3.16 

    　More details

    Event date： 2023.3

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  14. 福島ワクチンコホートのデータ解析 Invited

    岩見真吾

    現場からの医療改革推進協議会 第17回シンポジウム  2022.11.27 

    　More details

    Event date： 2022.11

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  15. ウイルス排出量の不均一性を考慮したCOVID-19感染者隔離戦略の定量的分析

    岩見真吾

    第69回日本ウイルス学会学術集会  2022.11.15 

    　More details

    Event date： 2022.11

    Language：Japanese   Presentation type：Oral presentation (general)  

  16. デジタルツイン時代の医薬品の橋渡し研究 Invited

    岩見真吾

    創薬薬理フォーラム第30回シンポジウム  2022.10.14 

    　More details

    Event date： 2022.10

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  17. Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan Invited International conference

    Shingo Iwami

    The 20th Awaji International Forum on Infection and Immunity, Research Institute for Microbial Diseases  2020.9.9 

    　More details

    Event date： 2022.9

    Language：English   Presentation type：Oral presentation (invited, special)  

  18. 数理モデル駆動型のデータ解析

    岩見真吾

    2022年度　日本数理生物学会  2022.9.5 

    　More details

    Event date： 2022.9

    Language：Japanese   Presentation type：Oral presentation (general)  

  19. デジタルツイン時代のCOVID-19研究 Invited

    岩見真吾

    第49回日本毒性学会学術年会 シンポジウム  2022.7.1 

    　More details

    Event date： 2022.6 - 2022.7

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  20. デジタルツイン時代の感染症創薬研究 Invited

    岩見真吾

    第63回 日本臨床ウイルス学会 シンポジウム4  2022.6.19 

    　More details

    Event date： 2022.6

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  21. 異分野融合研究で挑む定量的疾患研究 Invited

    岩見真吾

    日本生化学会 北陸支部 第40回大会 シンポジウム  2022.6.4 

    　More details

    Event date： 2022.6

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  22. 数理モデルを駆使した定量的データ解析の役割 Invited

    岩見真吾

    第58回 日本肝臓学会総会 特別企画4 テクニカルセミナー  2022.6.3 

    　More details

    Event date： 2022.6

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

  23. 数理モデル駆動型の未病研究 -不均一性と層別化- Invited

    岩見真吾

    日本生理学会第100回記念大会  2022.3.16 

    　More details

    Event date： 2022.3

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

▼display all

To the head of Presentations.▲

KAKENHI (Grants-in-Aid for Scientific Research) 6

  1. 感染症対策が駆動する新型コロナウイルスの進化予測とウィズコロナ 更新日

    Grant number：23H03497  2023.4 - 2026.3

    科学研究費助成事業 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\15900000 （ Direct Cost: \14400000 、 Indirect Cost：\1500000 ）

  2. 尿中蛋白質断片の網羅的解析による日和見感染症の新規診断法の開発

    Grant number：22K08583  2022 - 2024

    科学研究費助成事業  基盤研究（Ｃ）

    岩見 真吾

    　 More details

    Authorship：Coinvestigator(s) 

    Grant amount：\4290000 （ Direct Cost: \3300000 、 Indirect Cost：\990000 ）

  3. 新興感染症発生時における創薬加速のための数理情報基盤技術の確立

    Grant number：22K19829  2022 - 2023

    科学研究費助成事業  挑戦的研究（萌芽）

    岩見 真吾

    　 More details

    Authorship：Principal investigator 

    Grant amount：\6500000 （ Direct Cost: \5000000 、 Indirect Cost：\1500000 ）

  4. 異分野融合研究で解明するコロナ禍の当事者化

    Grant number：22H05215  2022 - 2023

    科学研究費助成事業  学術変革領域研究（Ａ）

    岩見 真吾

    　 More details

    Authorship：Principal investigator 

    Grant amount：\6900000 （ Direct Cost: \6000000 、 Indirect Cost：\900000 ）

  5. Mathematical sciences in aging and diversity of hematopoietic stem cell

    Grant number：20H05042  2020.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)

    　 More details

    Authorship：Principal investigator 

    Grant amount：\6240000 （ Direct Cost: \4800000 、 Indirect Cost：\1440000 ）

  6. 遺伝子配列に刻まれた宿主と病原体の攻防を読み解くビックデータ生態学の創成

    Grant number：16H04845  2016 - 2020

    科学研究費助成事業  基盤研究（Ｂ）

    岩見 真吾

    　 More details

    Authorship：Principal investigator 

    Grant amount：\17290000 （ Direct Cost: \13300000 、 Indirect Cost：\3990000 ）

▼display all

To the head of KAKENHI (Grants-in-Aid for Scientific Research).▲
 

Teaching Experience (On-campus) 2

  1. 超分子機能学講究４

    2021

  2. 超分子機能学特論４

    2021

To the head of Teaching Experience (On-campus).▲
 

Social Contribution 2

  1. “数学”で医学を変えられるか？

    Role(s)：Lecturer

    灘中学校・灘高等学校  灘中学校・灘高等学校  2021.10

    　More details

    Audience： Junior students,　High school students

    Type：Visiting lecture

  2. 感染症はなぜ流行するんだろ？

    Role(s)：Lecturer

    大阪府立泉陽高校(Zoom)  大阪府立泉陽高校(Zoom)  2021.6

    　More details

    Audience： High school students

    Type：Visiting lecture

To the head of Social Contribution.▲

Media Coverage 182

  1. エムポックスの隔離終了を合理的に決めるモデルを開発 名古屋大など Internet

    Yahoo!ニュース  2024.9

    　More details

    Author：Myself 

  2. エムポックスの隔離終了を合理的に決めるモデルを開発 名古屋大など Internet

    サイエンスポータル  2024.9

    　More details

    Author：Myself 

  3. PCR で隔離 1 週間短縮も 名大の研究チーム、エムポックスから推定 Newspaper, magazine

    神戸新聞 夕刊  2024.9

    　More details

    Author：Myself 

  4. PCR で隔離 1 週間短縮も 名大の研究チーム、エムポックスから推定 Newspaper, magazine

    中部経済新聞 朝刊  3面  2024.8

    　More details

    Author：Myself 

  5. エムポックス 検出期間個人差数倍 「20〜50 日程度」名大などのチーム発表 Newspaper, magazine

    朝日新聞 夕刊  8面  2024.8

    　More details

    Author：Myself 

  6. エムポックス発症者の隔離解除は「PCR 検査で」回復にばらつき Newspaper, magazine

    毎日新聞 朝刊  20面  2024.8

    　More details

    Author：Myself 

  7. エムポックス、PCR 検査で隔離 1 週間短く 名大分析 Newspaper, magazine

    日本経済新聞  2024.8

    　More details

    Author：Myself 

  8. エムポックス 50 日以上ウイルス検出の患者も 個人差数倍、名大解析 Internet

    朝日新聞デジタル  2024.8

    　More details

    Author：Myself 

  9. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    livedoor News  2024.8

    　More details

    Author：Myself 

  10. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    南日本新聞  2024.8

    　More details

    Author：Myself 

  11. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    福井新聞  2024.8

  12. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    中國新聞デジタル  2024.8

    　More details

    Author：Myself 

  13. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    山陽新聞デジタル  2024.8

    　More details

    Author：Myself 

  14. サル痘感染者の隔離期間を検証 名大チーム手法開発 Newspaper, magazine

    静岡新聞  2024.8

    　More details

    Author：Myself 

  15. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    茨城新聞クロスアイ  2024.8

    　More details

    Author：Myself 

  16. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    佐賀新聞  2024.8

    　More details

    Author：Myself 

  17. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    下野新聞社  2024.8

    　More details

    Author：Myself 

  18. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    徳島新聞  2024.8

  19. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    埼玉新聞  2024.8

    　More details

    Author：Myself 

  20. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    北海道新聞デジタル  2024.8

    　More details

    Author：Myself 

  21. エムポックス発症者の隔離解除は「PCR 検査で」回復にばらつき Internet

    毎日新聞デジタル  2024.8

    　More details

    Author：Myself 

  22. エムポックス発症者の隔離解除は「PCR 検査で」回復にばらつき Internet

    goo ニュース  2024.8

    　More details

    Author：Myself 

  23. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    東京新聞 TOKYO Web  2024.8

    　More details

    Author：Myself 

  24. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    Yahoo!ニュース  2024.8

    　More details

    Author：Myself 

  25. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    山陰中央新報デジタル  2024.8

    　More details

    Author：Myself 

  26. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    産経ニュース  2024.8

    　More details

    Author：Myself 

  27. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    新潟日報デジタルプラス  2024.8

    　More details

    Author：Myself 

  28. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    京都新聞  2024.8

    　More details

    Author：Myself 

  29. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    奈良新聞  2024.8

    　More details

    Author：Myself 

  30. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    西日本新聞 me  2024.8

    　More details

    Author：Myself 

  31. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    北日本新聞 webun プラス  2024.8

    　More details

    Author：Myself 

  32. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Internet

    沖縄タイムスプラス  2024.8

  33. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    四国新聞  2024.8

    　More details

    Author：Myself 

  34. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    沖縄タイムスプラス  2023.12

  35. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Newspaper, magazine

    共同通信  2023.12

  36. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    南日本新聞 373 る  2023.12

  37. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    東京新聞 TOKYO Web  2023.12

  38. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Newspaper, magazine

    千葉日報  2023.12

  39. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Newspaper, magazine

    埼玉新聞  2023.12

  40. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    茨城新聞クロスアイ  2023.12

  41. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    新潟日報デジタルプラス  2023.12

  42. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Newspaper, magazine

    佐賀新聞  2023.12

  43. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    北日本新聞 webun プラス  2023.12

  44. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    北國新聞デジタル  2023.12

  45. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Newspaper, magazine

    岩手日報  2023.12

  46. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止」 Internet

    山形新聞オンライン  2023.12

  47. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    Web 東奥  2023.12

  48. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    神戸新聞 NEXT  2023.12

  49. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    西日本新聞 me  2023.12

  50. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    中國新聞デジタル  2023.12

  51. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    徳島新聞デジタル版  2023.12

  52. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    愛媛新聞 ONLINE  2023.12

  53. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    河北新報オンライン  2023.12

  54. 「鼻粘膜抗体がウイルス排出抑制？コロナ感染拡大防止も」 Internet

    山陽新聞デジタル  2023.12

  55. 「コロナ再感染 うつすリスク低減か 感染研など鼻腔の抗体分析」 Newspaper, magazine

    毎日新聞  23 面  2023.12

  56. 「新型コロナ再感染者は人にうつすリスク低減か」 Internet

    毎日新聞デジタル  2023.12

  57. 「新型コロナ再感染者は人にうつすリスク低減か」 Internet

    Yahoo!ニュース  2023.12

  58. 「コロナウイルス行動変容で進化」 Newspaper, magazine

    茨城新聞  17 面  2023.11

  59. 「行動変容でウイルス進化？」 Newspaper, magazine

    埼玉新聞  14 面  2023.11

  60. 「行動変容でコロナウイルス進化？　コロナ株解析、名古屋大」 Newspaper, magazine

    中部経済新聞  3 面  2023.11

  61. 「行動変容でウイルス進化か 3 密回避に対抗、感染力高める 名大チーム、コロナ株解析」 Newspaper, magazine

    岐阜新聞  20 面  2023.11

  62. 「コロナウイルス感染対策、ウイルス進化引き起こしたか 名大・北大など研究」 Newspaper, magazine

    朝日新聞  10 面  2023.11

  63. 「コロナウイルス感染力、人の行動変容で変化？名古屋大など」 Newspaper, magazine

    日本経済新聞  26 面  2023.11

  64. 「変異株ウイルス量増　感染者排出ピーク時」 Newspaper, magazine

    毎日新聞  20 面  2023.11

  65. 「コロナウイルス行動変容で進化」 Newspaper, magazine

    山陽新聞  4 面  2023.11

  66. 「ウイルスの進化に行動変容が影響？」 Newspaper, magazine

    山形新聞  17 面  2023.11

  67. 「行動変容でウイルス進化か」 Newspaper, magazine

    岐阜新聞  20 面  2023.11

  68. 「人との接触減でコロナ感染力増」 Newspaper, magazine

    四国新聞  3 面  2023.11

  69. 「行動変容でウイルス進化？」 Newspaper, magazine

    長崎新聞  2023.11

  70. “Wie Verhalten das Coronavirus veränderte” Internet

    science.orf.at  2023.11

  71. 「3 密回避や隔離がコロナを「進化」させた？ウイルス増・ピーク早く」 Internet

    朝日新聞デジタル  2023.11

  72. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Newspaper, magazine

    佐賀新聞  2023.11

  73. “How Lockdowns Shaped the Virus: AI Uncovers COVID-19’s Evolutionary Secrets” Internet

    SciTechDaily  2023.11

  74. “COVID's Evolution May Have Been Driven by Human Behavior, Say Biologists” Internet

    Newsweek  2023.11

  75. “Human behavior may drive the evolution of new coronavirus strains" Internet

    News Medical  2023.11

  76. 「行動変容でコロナウイルス進化？ 名古屋大、感染者のデータ解析」 Internet

    東京新聞 TOKYO Web  2023.11

  77. 「新型コロナ、変異でウイルス排出量 5 倍に ピークも 1.5 倍早まる」 Internet

    Yahoo!ニュース  2023.11

  78. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Newspaper, magazine

    北海道新聞  2023.11

  79. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    北國新聞デジタル  2023.11

  80. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    大分合同新聞 Gate  2023.11

  81. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    神戸新聞 NEXT  2023.11

  82. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Newspaper, magazine

    埼玉新聞  2023.11

  83. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    北日本新聞 webun プラス  2023.11

  84. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    新潟日報デジタルプラス  2023.11

  85. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    高知新聞 Plus  2023.11

  86. 「新型コロナ、変異でウイルス排出量 5 倍に ピークも 1.5 倍早まる」 Internet

    毎日新聞デジタル  2023.11

  87. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    沖縄タイムス＋プラス  2023.11

  88. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    福井新聞 ONLINE  2023.11

  89. 「行動変容でウイルス進化か 名大チーム、コロナ株解析 ３密回避に対抗、感染力高める」 Internet

    岐阜新聞 Web  2023.11

  90. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    西日本新聞 me  2023.11

  91. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Internet

    河北新報 ONLINE  2023.11

  92. 「行動変容でコロナウイルス進化？名古屋大、感染者のデータ解析」 Newspaper, magazine

    共同通信社  2023.11

  93. 「新型コロナ　毎日抗原検査、クラスター３割に　発症前や無症状、適切隔離で抑制」 Newspaper, magazine

    毎日新聞  21 面  2023.11

  94. 「クラスター低減には抗原検査が有効　名古屋大などが発生確率計算」 Internet

    毎日新聞デジタル  2023.10

  95. 「抗原検査でクラスター低減」 Newspaper, magazine

    中部経済新聞  3 面  2023.10

  96. 「クラスター発生率毎日検査で 20%減」 Newspaper, magazine

    岐阜新聞  19 面  2023.10

  97. 「新型コロナクラスター 定期的な検査で大幅減」 Newspaper, magazine

    長崎新聞  2023.10

  98. 「定期的抗原検査でクラスター低減」 Newspaper, magazine

    熊本日日新聞  20 面  2023.10

  99. 「クラスター低減効果 未発症者ら定期的抗原検査」 Newspaper, magazine

    南日本新聞  22 面  2023.10

  100. 「定期抗原検査でクラスター低減」 Newspaper, magazine

    愛媛新聞  2023.10

  101. 「コロナクラスター低減 他の感染症にも応用可」 Newspaper, magazine

    秋田魁新報  3 面  2023.10

  102. 「検査でクラスター低減 コロナ発生確率計算」 Newspaper, magazine

    日本海新聞  22 面  2023.10

  103. 「検査でクラスター低減効果 新型コロナ計算、名古屋大」 Newspaper, magazine

    共同通信社  2023.10

  104. ＰＣＲ検査で隔離１週間短縮も エムポックス推定、名古屋大 Newspaper, magazine

    埼玉新聞  2023.8

    　More details

    Author：Myself 

  105. 「感染症対策に数学的手法」 Newspaper, magazine

    読売新聞  24面  2023.6

    　More details

    Author：Myself 

  106. 「P/F 比と血液検査から COVID-19 の治療反応性を事前予測――日本生理学会レポート」 Internet

    m3.com オンライン  2023.5

    　More details

    Author：Myself 

  107. 「４日後再陰性でリスク１％以下 療養後に感染させる可能性」 Newspaper, magazine

    中日新聞  1面  2022.9

    　More details

    Author：Myself 

  108. 「隔離解除 計算で判断 名大など開発 「ウィズコロナ」見据え」 Newspaper, magazine

    毎日新聞  24面  2022.9

    　More details

    Author：Myself 

  109. 「肺炎治療薬などサル痘に有効か」 Newspaper, magazine

    神戸新聞  6面  2022.8

    　More details

    Author：Myself 

  110. 「既存薬３種類サル痘有効か」 Newspaper, magazine

    北海道新聞  26面  2022.8

    　More details

    Author：Myself 

  111. 「サル痘既存薬３種有効」 Newspaper, magazine

    東京新聞  3面  2022.8

    　More details

    Author：Myself 

  112. 「サル痘、既存薬有効か」 Newspaper, magazine

    秋田魁新報  3面  2022.8

    　More details

    Author：Myself 

  113. 「サル痘の治療薬候補 3 種類を発見」 Newspaper, magazine

    毎日新聞  2面  2022.8

    　More details

    Author：Myself 

  114. 「肺炎治療薬などサル痘に有効か」 Newspaper, magazine

    沖縄タイムス  24面  2022.8

    　More details

    Author：Myself 

  115. 「肺炎治療薬などサル痘に有効か」 Newspaper, magazine

    熊本日日新聞  4面  2022.8

    　More details

    Author：Myself 

  116. 「サル痘に肺炎治療薬有効か」 Newspaper, magazine

    東奥日報  25面  2022.8

    　More details

    Author：Myself 

  117. 「サル痘肺炎治療薬有効か」 Newspaper, magazine

    岩手日報  4 面  2022.8

    　More details

    Author：Myself 

  118. 「サル痘、肺炎治療薬有効か」 Newspaper, magazine

    日本経済新聞  36面  2022.8

    　More details

    Author：Myself 

  119. 「サル痘に肺炎薬有効か」 Newspaper, magazine

    産経新聞東京  18面  2022.8

    　More details

    Author：Myself 

  120. 「サル痘に肺炎薬有効か」 Newspaper, magazine

    産経新聞大阪  19面  2022.8

    　More details

    Author：Myself 

  121. 「サル痘肺炎治療薬有効か」 Newspaper, magazine

    茨城新聞  4面  2022.8

    　More details

    Author：Myself 

  122. 「サル痘に肺炎治療薬有効か」 Newspaper, magazine

    千葉日報  17面  2022.8

    　More details

    Author：Myself 

  123. 「３種の既存薬サル痘有効か」 Newspaper, magazine

    神奈川新聞  21面  2022.8

    　More details

    Author：Myself 

  124. 「肺炎治療薬などサル痘に有効か」 Newspaper, magazine

    埼玉新聞  15面  2022.8

    　More details

    Author：Myself 

  125. 「サル痘に既存薬有効か」 Newspaper, magazine

    新潟日報  29面  2022.8

    　More details

    Author：Myself 

  126. 「サル痘既存３薬有効か」 Newspaper, magazine

    中日新聞  25面  2022.8

    　More details

    Author：Myself 

  127. 「サル痘に肺炎治療薬有効か」 Newspaper, magazine

    中部経済新聞  13面  2022.8

    　More details

    Author：Myself 

  128. 「サル痘に肺炎治療薬有効か」 Newspaper, magazine

    伊勢新聞  15面  2022.8

    　More details

    Author：Myself 

  129. 「サル痘にコロナ薬有効か」 Newspaper, magazine

    北日本新聞  27面  2022.8

    　More details

    Author：Myself 

  130. 「肺炎治療薬などサル痘に有効か」 Newspaper, magazine

    北國新聞  33面  2022.8

    　More details

    Author：Myself 

  131. 「サル痘肺炎治療薬有効か」 Newspaper, magazine

    福井新聞  4面  2022.8

    　More details

    Author：Myself 

  132. 「サル痘に肺炎治療薬有効か」 Newspaper, magazine

    北陸中日新聞  27面  2022.8

    　More details

    Author：Myself 

  133. 「サル痘ウイルスに肺炎治療薬有効か」 Newspaper, magazine

    京都新聞  25 面  2022.8

    　More details

    Author：Myself 

  134. 「肺炎治療薬など３種サル痘に有効か」 Newspaper, magazine

    山陽新聞  4 面  2022.8

    　More details

    Author：Myself 

  135. 「３種の既存薬がサル痘に有効か」 Newspaper, magazine

    中国新聞  28面  2022.8

    　More details

    Author：Myself 

  136. 「サル痘肺炎治療薬有効か」 Newspaper, magazine

    日本海新聞  23面  2022.8

    　More details

    Author：Myself 

  137. 「抗コロナ薬など既存３種 サル痘治療に有効」

    四国新聞  5面  2022.8

  138. 「肺炎・新型コロナ・マラリア サル痘既存３薬有効か」 Newspaper, magazine

    愛媛新聞  3面  2022.8

    　More details

    Author：Myself 

  139. 「既存薬の３種サル痘に有効か」

    徳島新聞  20面  2022.8

  140. 「サル痘 肺炎治療薬有効？」 Newspaper, magazine

    西日本新聞  19面  2022.8

    　More details

    Author：Myself 

  141. 「肺炎治療薬などサル痘に有効か 候補３種絞り込み」

    長崎新聞  20面  2022.8

  142. 「肺炎治療の既存薬 サル痘に有効か」 Newspaper, magazine

    大分合同新聞  17面  2022.8

  143. 「サル痘に肺炎治療薬有効か」 Newspaper, magazine

    佐賀新聞  20面  2022.8

  144. 「サル痘、肺炎治療薬が有効か」 Newspaper, magazine

    共同通信社  2022.8

    　More details

    Author：Myself 

  145. 「既存の肺炎薬や新型コロナ薬、サル痘に効果か」 Internet

    朝日新聞デジタル  2022.8

    　More details

    Author：Myself 

  146. 「新型コロナのワクチン 効果を６タイプに分類」 Newspaper, magazine

    読売新聞東京本社版  3面  2022.8

  147. 「サル痘の治療薬候補 3 種類を発見」 Internet

    毎日新聞デジタル  2022.8

    　More details

    Author：Myself 

  148. 「ワクチン効果６タイプ」 Newspaper, magazine

    読売新聞大阪本社版  2面  2022.8

    　More details

    Author：Myself 

  149. 「治験薬探し 治験の食い違いはなぜ」 Newspaper, magazine

    朝日新聞  28面  2021.11

    　More details

    Author：Myself 

  150. 「コロナ薬、治験早めれば増える？「投与は発症 2 日以内で」」 Internet

    朝日新聞オンライン  2021.10

    　More details

    Author：Myself 

  151. “Kyushu University investigate clinical trial design for the novel coronavirus infection with an eye on developing trial standard” Internet

    2021.9

    　More details

    Author：Myself 

  152. 「不要な隔離期間、短縮」 Newspaper, magazine

    毎日新聞  11面  2021.9

    　More details

    Author：Myself 

  153. 「コロナ患者の隔離期間試算」 Newspaper, magazine

    読売新聞  6面  2021.8

  154. 「発症後すぐ調べ効率的に」 Newspaper, magazine

    毎日新聞  3面  2021.8

  155. 「名古屋大など、新型コロナの適切な隔離期間計算、シミュレーションソフト開発」 Newspaper, magazine

    化学工業日報  5面  2021.8

  156. 「コロナ治療薬、早期投与かぎ」 Newspaper, magazine

    西日本新聞  9面  2021.8

  157. 「コロナ薬 早期投与が鍵」 Newspaper, magazine

    山梨日日新聞  12面  2021.8

    　More details

    Author：Myself 

  158. 「コロナ隔離期間の試算法開発」 Newspaper, magazine

    読売新聞  3面  2021.8

    　More details

    Author：Myself 

  159. 「コロナ薬効果の臨床治験 発症後早期投与が鍵」 Newspaper, magazine

    茨城新聞  17面  2021.8

  160. 「コロナ治療薬候補の効果確認 発症直後の早期投与が鍵」 Newspaper, magazine

    下野新聞  16面  2021.8

    　More details

    Author：Myself 

  161. 「コロナ薬治療 早期投与が鍵」 Newspaper, magazine

    神戸新聞  14面  2021.8

    　More details

    Author：Myself 

  162. 「治療薬の治験 早期投与が鍵」 Newspaper, magazine

    信濃毎日新聞  13面  2021.8

  163. 「コロナ薬 早期投与が鍵」 Newspaper, magazine

    埼玉新聞  13面  2021.8

  164. 「コロナ薬治療 早期投与が鍵」 Newspaper, magazine

    佐賀新聞  15面  2021.8

  165. 「コロナ薬治験 早期投与が鍵 仮想システム活用し確認」 Newspaper, magazine

    琉球新報  17面  2021.8

    　More details

    Author：Myself 

  166. 「コロナ薬 早期投与が鍵「バーチャル治験」で解明 」 Newspaper, magazine

    東奥日報  8面  2021.8

  167. 医療新世紀「コロナ薬、早期投与が鍵」 Newspaper, magazine

    千葉日報  14面  2021.8

    　More details

    Author：Myself 

  168. 医療新世紀「コロナ薬、早期投与が鍵」 Internet

    宮崎日日新聞オンライン  2021.8

  169. 医療新世紀「コロナ薬、早期投与が鍵」 Newspaper, magazine

    山口新聞  5面  2021.8

    　More details

    Author：Myself 

  170. 医療新世紀「コロナ治療薬 早期投与が鍵」

    デーリー東北  19面  2021.8

    　More details

    Author：Myself 

  171. 「新型コロナ治療薬は早期投与が鍵か 治験での効果確認で研究結果」 Internet

    京都新聞オンライン  2021.7

    　More details

    Author：Myself 

  172. 「コロナ患者隔離「10 日間は妥当」」 Internet

    中日新聞オンライン  2021.7

    　More details

    Author：Myself 

  173. 「コロナ患者隔離「10 日間は妥当」」 Newspaper, magazine

    中日新聞  25面  2021.7

    　More details

    Author：Myself 

  174. 「新型コロナ感染症の臨床試験シミュレータ開発」 Newspaper, magazine

    科学新聞  ４面  2021.7

    　More details

    Author：Myself 

  175. 「コロナ治験、より早く」 Internet

    中日新聞オンライン  2021.7

    　More details

    Author：Myself 

  176. 「ウイルス感染 陰性まで７～２８日」 Newspaper, magazine

    読売新聞  3面  2021.7

    　More details

    Author：Myself 

  177. 「ウイルス残る期間は７～２８日程度、個人差あり臨床試験の「壁」に」 Internet

    読売新聞オンライン  2021.7

    　More details

    Author：Myself 

  178. 「数理モデルによる臨床試験シミュレータを開発」 Internet

    日本経済新聞オンライン  2021.7

  179. 「コロナ治験、より早く」 Newspaper, magazine

    中日新聞  2面  2021.7

    　More details

    Author：Myself 

  180. 「薬がよく効くのは発症後２日程度」 Newspaper, magazine

    朝日新聞  22面  2021.4

    　More details

    Author：Myself 

  181. 「薬がよく効くのは発症後２日程度」 Internet

    朝日新聞オンライン  2021.4

    　More details

    Author：Myself 

  182. 「有効性見極め難しく」 Newspaper, magazine

    東京新聞  12 面  2021.4

    　More details

    Author：Myself 

▼display all

To the head of Media Coverage.▲